Uncategorized

Vaccine Efficacy Questions

  • by

Next up on the vaccine news front are some concerns about efficacy. In a very surprising statement, Gao Fu (the head of the Chinese Center for Disease Control and Prevention) said at a conference in Chengdu over the weekend that that the protection figures of… Read More »Vaccine Efficacy Questions

Global Pharmacovigilance Observatory to aid pharma’s understanding of regulatory decisions

  • by

The UK’s Drug Safety Research Unit (DSRU) has launched a Global Pharmacovigilance Observatory to help the pharma industry understand why international regions reach different decisions on the use of medicines. The observatory will review and collate pharmacovigilance and drug safety data, analyses, evaluations and decisions… Read More »Global Pharmacovigilance Observatory to aid pharma’s understanding of regulatory decisions

New group to tackle data governance and guide digital transformation in pharma

  • by

The Pistoia Alliance, a global, not-for-profit alliance advocating for greater collaboration in life sciences R&D, has launched its Data Governance Community of Interest (CoI). The CoI was set up after a roundtable discussion assessing industry priorities, attended by professionals from pharma companies such as AbbVie,… Read More »New group to tackle data governance and guide digital transformation in pharma

GSK Consumer Healthcare to incorporate paper bottles into its packaging

  • by

GlaxoSmithKline Consumer Healthcare (GSKCH) has joined the Pulpex paper bottle partner consortium and will explore incorporating recyclable paper bottles into its packaging. The partnership is part of GSKCH’s commitment for all consumer product packaging to be recyclable or reusable, including eliminating all problematic and unnecessary… Read More »GSK Consumer Healthcare to incorporate paper bottles into its packaging

Androgen Receptors for COVID-19

  • by

There’s a report of an interesting small-molecule drug effort against the coronavirus that seems to have produced rather significant results. The idea goes back to effects that were noticed last year – for example, in this population-based study from Italy. It’s been known since the… Read More »Androgen Receptors for COVID-19

Home Health Giants Double Down on Diversion, as Nursing Home Numbers Normalize

  • by

Acute and post-acute patient volumes started to normalize in the early part of 2021, with hospitals, skilled nursing facilities (SNFs) and home health providers all hovering around their 2019 baselines. The accelerated rollout of COVID-19 vaccines is largely responsible for the newfound stability, particularly in… Read More »Home Health Giants Double Down on Diversion, as Nursing Home Numbers Normalize

Early March Vaccine Thoughts

  • by

Some thoughts about the current vaccine trials and data, some of which are probably obvious, but which might be worth bringing together: First, as many have been mentioning, it’s tempting but quite difficult to compare the vaccines (and vaccine candidates) head-to-head by looking at their… Read More »Early March Vaccine Thoughts

Vetiver

  • by

In my experience, most organic and medicinal chemists are always ready to hear about the latest results in two branches of the science: things that explode and things with weird smells. Maybe we are in our way “singularly in touch with the primitive promptings of… Read More »Vetiver

The J&J Vaccine at the FDA

  • by

The briefing documents are out at the FDA site for tomorrow’s hearing on the J&J vaccine. Here’s a summary at STAT from Matthew Herper and Helen Branswell, and I agree with their take: overall, the numbers look good. Update: here’s a good Twitter thread from… Read More »The J&J Vaccine at the FDA

Cancer and Gene Therapy

  • by

There’s news today that Bluebird has suspended its gene therapy work on sickle cell disease because of two cases of cancer in its treatment population. Another had been reported in 2018, so that takes us to two cases of myelodysplastic syndrome and one case of… Read More »Cancer and Gene Therapy

GLP-1 and Obesity

  • by

Let’s have a look at a paper that came out recently in the New England Journal of Medicine. It shows strong results in a therapeutic area that a lot of people have spent a lot of effort on: obesity. I’ve been kicking around the idea… Read More »GLP-1 and Obesity

Novel ionic liquid enables uniform chemotherapy delivery in solid tumours

  • by

In preclinical studies, injection of a novel ionic liquid formulation (“locally active agent for tumour treatment and eradication” or LATTE) allowed uniform delivery of a chemotherapy drug in solid tumours. According to the study’s senior author, Dr Rahmi Oklu, a vascular and interventional radiologist at… Read More »Novel ionic liquid enables uniform chemotherapy delivery in solid tumours

First immunotherapy for advanced basal cell carcinoma approved in US

  • by

The US Food and Drug Administration (FDA) has approved the first immunotherapy for patients with advanced basal cell carcinoma (BCC). Libtayo® (cemiplimab-rwlc), a PD-1 inhibitor, was also granted accelerated approval in metastatic BCC. “Today’s FDA approval of Libtayo will change the treatment paradigm for patients… Read More »First immunotherapy for advanced basal cell carcinoma approved in US

ViewPoints Interview: ViiV Healthcare’s Duncan Short Shares Insight on PROgress Study Demonstrating that Pre-Visit Survey Can Improve HIV Care

  • by

In a recent interview with PharmaShots, Duncan Short, Ph.D., Director of Global Implementation Science at ViiV Healthcare shared his views on the findings of a new study demonstrating how the inclusion of a brief survey focused on patient-reported outcomes (PROs) during doctor’s appointments can improve HIV… Read More »ViewPoints Interview: ViiV Healthcare’s Duncan Short Shares Insight on PROgress Study Demonstrating that Pre-Visit Survey Can Improve HIV Care

Intranasal influenza vaccine produces strong immune response, Phase I study shows

  • by

An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response, a Phase I study has shown.  The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to haemagglutinin, a protein found on the surface of influenza… Read More »Intranasal influenza vaccine produces strong immune response, Phase I study shows

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA

  • by

This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve… The post The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA… Read More »The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA

NICE recommends Beovu (brolucizumab) for treatment of wet AMD

  • by

The UK National Institute for Health and Care Excellence (NICE) has issued final guidance, also known as Technology Appraisal Guidance (TAG), recommending Beovu® (brolucizumab) as an option in the National Health Service (NHS) for the treatment of neovascular (wet) age-related macular degeneration (AMD) in adults.  According to Novartis, which produces the drug,  the… Read More »NICE recommends Beovu (brolucizumab) for treatment of wet AMD

EMA initiates rolling review of Regeneron’s COVID-19 mAb

  • by

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has started a ‘rolling review’ of data on REGN-COV2 antibody combination (casirivimab/imdevimab) for the treatment and prevention of COVID-19. The treatment is being co-developed by Regeneron Pharmaceuticals and Roche. The CHMP’s decision to start the rolling review… Read More »EMA initiates rolling review of Regeneron’s COVID-19 mAb

Screening, Within and Without

  • by

So I’m a small-molecule drug discovery person at heart, since I started out as a synthetic organic chemist. Talking about vaccines and antibodies nonstop is a bit of a strain, then, because immunology is full of stuff that’s rather far removed from good ol’ small-molecule… Read More »Screening, Within and Without

J&J and Novavax Data

  • by

Suddenly we have a lot more vaccine efficacy data to discuss! Yesterday came an announcement from Novavax about trials they’ve been conducting in the UK and in South Africa with their recombinant protein vaccine, and today comes equally anticipated data from J&J (Janssen) on their… Read More »J&J and Novavax Data

EMA accepts MAA for Oxbryta to treat haemolytic anaemia in sickle cell disease

  • by

The European Medicines Agency (EMA) has accepted Global Blood Therapeutics (GBT) marketing authorisation application for Oxbryta® (voxelotor) for the treatment of haemolytic anaemia in sickle cell disease (SCD). According to the company, the EMA has now started its standard review process.  A first-in-class oral, once-daily therapy,… Read More »EMA accepts MAA for Oxbryta to treat haemolytic anaemia in sickle cell disease

Moderna COVID-19 vaccine successful against emerging variants, study shows

  • by

Moderna has announced results from in vitro neutralisation studies of sera from individuals vaccinated with the company’s COVID-19 vaccine showing activity against emerging strains of SARS-CoV-2. According to the company, vaccination with the Moderna COVID-19 vaccine (mRNA-1273) produced neutralising titers against all key emerging variants tested,… Read More »Moderna COVID-19 vaccine successful against emerging variants, study shows

AstraZeneca and Care Access Research Collaborate on Decentralized COVID-19 Clinical Trial

  • by

What You Should Know: – AstraZeneca and Care Access Research are teaming up to provide decentralized, mobile research site operations for AstraZeneca’s AZD7442 phase III clinical trial in the US. – The Phase III clinical trial called STORM CHASER will assess the safety and efficacy… Read More »AstraZeneca and Care Access Research Collaborate on Decentralized COVID-19 Clinical Trial

Cognizant and XPRIZE Announce Finalists For $500k COVID-19 Pandemic Response Competition

  • by

What You Should Know: – Cognizant, a Fortune 200 leader in technology and professional services, recently partnered with XPRIZE on the Pandemic Response Challenge, a global competition aimed at fighting the pandemic and mapping a course for safely reopening societies using artificial intelligence. The challenge… Read More »Cognizant and XPRIZE Announce Finalists For $500k COVID-19 Pandemic Response Competition

Amneal Pharmaceuticals Pvt. Ltd- Walk-In Interviews (50 Openings) for Manufacturing / Quality Control On 31st Jan’ 2021

  • by

Amneal Pharmaceuticals Pvt. Ltd- Walk-In Interviews (50 Openings) for Manufacturing / Quality Control On 31st Jan’ 2021 Job Description Amneal Pharma -Openings for Injectable Manufacturing & Quality Control Sterile Manufacturing (Ophthalmic, PFS and Vial Line) Designation: Executive/ Sr. Officer/ Officer/ Operators Qualification: M. Pharma/ B. Pharma/ Diploma… Read More »Amneal Pharmaceuticals Pvt. Ltd- Walk-In Interviews (50 Openings) for Manufacturing / Quality Control On 31st Jan’ 2021

The Other Guys

  • by

Writing the other day about the lipid formulations used in the current mRNA vaccines makes me want to highlight something else that I hit on from time to time around here. When you learn in school about the major classes of biomolecules, you hear about… Read More »The Other Guys

87% of Americans Want to Receive COVID-19 Vaccine Information From Their Providers

  • by

What You Should Know: According to a recent Updox survey, 87% of Americans say they want to receive information from their healthcare provider on COVID-19 vaccine-related news/updates, with their healthcare providers cited as the most trusted source on the topic (34%) — behind health protection… Read More »87% of Americans Want to Receive COVID-19 Vaccine Information From Their Providers

Solving the 50-Year-Old EHR’s Midlife Crisis: How Platform EHRs are Finally Delivering Clinical Intelligence

  • by

Over its first 50 years in existence, how did the EHR lose its way? Given that EHR adoption doubled between 2007 and 2012 and EHR expenditures in the United States grew an annual average of 5.4% from 2015 to 2019, totaling $14.5 billion in 2019,… Read More »Solving the 50-Year-Old EHR’s Midlife Crisis: How Platform EHRs are Finally Delivering Clinical Intelligence

Biopharma industry commits to working with regulatory agencies on COVID-19 vaccines

  • by

A joint statement from a range of biopharmaceutical industry groups has said they recognise that with the first COVID-19 vaccines authorised by regulatory authorities and administered to the public, a critical new phase of the pandemic has begun. The statement was released by the International Federation… Read More »Biopharma industry commits to working with regulatory agencies on COVID-19 vaccines

European Commission approves dispersible tablets to treat paediatric HIV

  • by

The European Commission (EC) has granted marketing authorisation for Tivicay (dolutegravir) 5mg dispersible tablets, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients. ViiV Healthcare, which produces the tablets, said that… Read More »European Commission approves dispersible tablets to treat paediatric HIV

More Things to Do With mRNA

  • by

After yesterday’s post on mRNA vaccines and RNA mechanisms, I wanted to highlight a completely non-coronavirus application that has recently appeared in the literature. It’s from BioNTech, the German company who’s been working with Pfizer on one of the two mRNA coronavirus vaccines, of course,… Read More »More Things to Do With mRNA

First patient dosed with COVI-VAC, an intranasal COVID-19 vaccine candidate

  • by

The first patient has been dosed in the Phase 1 clinical trial of COVI-VAC, a single-dose, intranasal, live attenuated vaccine against SARS-CoV-2, the virus that causes COVID-19. The randomised, double-blinded, placebo-controlled dose-escalation study will evaluate the safety and tolerability COVI-VAC at multiple dose levels in… Read More »First patient dosed with COVI-VAC, an intranasal COVID-19 vaccine candidate

Variants and Vaccines

  • by

Well, here I am with the first “In the Pipeline” post of 2021, and damn itall, I’m right back to the stuff I was writing about last time. I still expect this year to be the time when we beat back the coronavirus pandemic, and… Read More »Variants and Vaccines

Concerns raised over India’s approval of COVID-19 vaccine with incomplete data

  • by

Following India’s approval of the internally developed Covaxin COVID-19 vaccine, experts have raised concerns over whether the jab should have been authorised without sufficient publication of its safety and efficacy data. The vaccine has been given permission to be used “in clinical trial mode… specifically… Read More »Concerns raised over India’s approval of COVID-19 vaccine with incomplete data

Holiday Break

  • by

I’ll be taking a holiday break, with intermittent blogging. I hope to put in a recipe or two (as often happens around here this time of year), and I’ll certainly pop up if we have some big news. Otherwise, from now until January 2nd I’ll… Read More »Holiday Break

The New Mutations

  • by

OK, time to write about the topic that’s been the talk of the coronavirus world the last day or two: the new strain that has been detected in the UK. I’ll go ahead and put the bottom line right here, and then go into the… Read More »The New Mutations

Autoantibody Problems

  • by

Here’s a preprint from a large team at Yale with a close look at a less-studied aspect of coronavirus infection. It’s been well established by now that a feature of severe cases is a misfiring immune response (the “cytokine storm”, etc.), and one reason that… Read More »Autoantibody Problems

Protein Folding, 2020

  • by

Every two years there’s a big challenge competition in predicting protein folding. That is. . .well, a hard problem. Protein chains have (in theory) an incomprehensibly large number of possible folded states, but many actual proteins just manage to arrange themselves properly either alone or… Read More »Protein Folding, 2020

Philips Unveils Vendor-Neutral Radiology Operations Command Center, Automated Radiology Workflow Suite

  • by

What You Should Know: – Philips unveils a new multimodality virtual imaging command center that enables real-time, remote collaboration to broaden expertise between technologists, radiologists, and imaging operations teams across multiple sites via private, secure telepresence capabilities. – In addition, Philips debuts AI-enabled, automated Radiology Workflow… Read More »Philips Unveils Vendor-Neutral Radiology Operations Command Center, Automated Radiology Workflow Suite

Vaccine Possibilities

  • by

Now that we’re seeing that coronavirus vaccines are indeed possible (and are on their way), let’s talk about the remaining unanswered questions and the things that we will be getting more data on. Here are some of the big issues – it’ll be good to… Read More »Vaccine Possibilities

Innovaccer, Surescripts Integrate to Leverage Medication Data for Patients

  • by

What You Should Know: – Innovaccer partners with Surescripts to power its data activation platform with the most comprehensive medication data. – The partnership will enable the company to conduct smart medication reconciliation and ensure that patients are complying with their care protocols. Innovaccer, Inc.,… Read More »Innovaccer, Surescripts Integrate to Leverage Medication Data for Patients

Vaccine Efficacy Data!

  • by

Earlier this morning, Pfizer and BioNTech announced the first controlled efficacy data for a coronavirus vaccine. And the news is good. You may recall that these vaccine trials are set up to get to a defined number of coronavirus cases overall, at which time the… Read More »Vaccine Efficacy Data!

Aducanumab at the FDA

  • by

So it’s finally time for Biogen to sit down with an FDA advisory committee to look at their proposed Alzheimer’s therapy, the anti-amyloid antibody aducanumab. I last wrote about it here, back in December, and you know what? I haven’t changed my mind a bit,… Read More »Aducanumab at the FDA

Shodhana Laboratories-Walk-In Interviews for Freshers On 4th Nov’ to 7th Nov’ 2020

  • by

Shodhana Laboratories-Walk-In Interviews for Freshers On 4th Oct’ to 7th Nov’ 2020 Walk-In Interviews for B.Pharm/ M.Pharm/ M.Sc/ Any Degree Freshers @ Shodhana Laboratories Limited Job Description We are happy to provide an Opportunity for Freshers Qualification: Any Degree, B.Pharmacy, M.Pharmacy, M.Sc, Any Other Graduation. (Only For… Read More »Shodhana Laboratories-Walk-In Interviews for Freshers On 4th Nov’ to 7th Nov’ 2020

Longevity

  • by

Wouldn’t be great if we could find a treatment to improve longevity? Not just a treatment for a specific disease but one that could dramatically improve longevity for a large percentage of human kind. While there is a lot of longevity research going on and… Read More »Longevity

Down to the Atoms

  • by

I wanted to mention something that was reported a week or so ago, and may sound a bit exotic or obscure, if you’re not a structural biologist. But it’s yet another sign of a revolution in our ability to get structures of biomolecules (and others)… Read More »Down to the Atoms

Click Chemotherapy

  • by

So here’s an ambitious idea that’s about to get a hearing in human clinical trials. A startup called Shasqi is using click chemistry as a drug delivery method, and they have a new manuscript on the idea here at ChemRxiv. The idea is this: you… Read More »Click Chemotherapy

More Antibody Data

  • by

Unfortunately, we’re getting a dose these days of “That’s why you run clinical trials”. Word came Monday evening (Peter Loftus in the WSJ, and a Lilly statement) that the ACTIV-3 trial being run by the NIH has shown lack of efficacy for the combination of… Read More »More Antibody Data

Medtronic’s Abre Venous Stent Receives the US FDA’s Approval to Treat Venous Outflow Obstruction

  • by

Shots: The approval is based on ABRE clinical study assessing the Abre stent in 200 patients with iliofemoral venous outflow obstruction across the spectrum of deep venous obstruction including those with the post-thrombotic syndrome, NIVL & those who presented with an aDVT. The study also… Read More »Medtronic’s Abre Venous Stent Receives the US FDA’s Approval to Treat Venous Outflow Obstruction

The Vaccine Tightrope

  • by

We’re getting closer to having to deal with a number of tricky issues around the first Emergency Use Authorizations (EUAs) for coronavirus vaccines. These have never quite come up in this way before, because (for one thing) EUAs for vaccines are relatively rare events, and… Read More »The Vaccine Tightrope

The Machines Rise a Bit More

  • by

Here’s a new paper in Nature on computer-generated synthesis of natural products. More formally, you’d call it retrosynthesis, since the htought process in organic chemistry tends to work backwards when you have a particular target that you’re trying to make: “OK, this part could could… Read More »The Machines Rise a Bit More

The SOLIDARITY Data

  • by

OK, we have some more to think about this morning. The large SOLIDARITY trial from the WHO has reported more interim data on its investigation into repurposed drugs for the coronavirus pandemic. And some of this we already knew, but some of it’s a real… Read More »The SOLIDARITY Data

Immunity and Re-Infection

  • by

For months now, people have been watching closely to see if it’s possible to get re-infected with the coronavirus. It’s taken a while for the signal-to-noise to get better, but by now there’s no doubt that the answer is yes, it’s possible. We’ve just had… Read More »Immunity and Re-Infection

Another Vaccine Trial Halt

  • by

The first advice is “Don’t panic”. You will have heard that last night J&J announced that their coronavirus vaccine dosing has been paused while they investigate an adverse event in the trial. And while you never like to hear that, considering the size of their… Read More »Another Vaccine Trial Halt

Cigna’s Evernorth Expands Digital Health Formulary with Addition of Omada MSK by Physera

  • by

What You Should Know: – Cigna Corporation’s health services segment, Evernorth expands its digital health formulary with the addition of Omada MSK by Physera. – Omada MSK by Physera joins Omada’s existing formulary programs for diabetes prevention, type 2 diabetes, and hypertension. Cigna Corporation’s health… Read More »Cigna’s Evernorth Expands Digital Health Formulary with Addition of Omada MSK by Physera

A Nobel for CRISPR

  • by

The 2020 Chemistry Nobel has gone to Jennifer Doudna and Emmanuelle Charpentier for the discovery of CRISPR. An award in this area has been expected for some time – it’s obviously worthy – so the main thing people have been waiting for is to see… Read More »A Nobel for CRISPR

2020 Cold Chain Provider Directory

  • by

Download the 2020 Cold Chain Vendor and Service Provider Directory here. The post 2020 Cold Chain Provider Directory appeared first on Pharmaceutical Commerce.

Should more flexible health care professional licensing continue after COVID-19?

  • by

Shirley Svorny and Michael Cannon of the Cato Institute have a long history (see here) of criticizing government licensing of physicians and other health care providers (e.g., nurse practitioners [NPs], nurses). Their proposed alternative has been to allow private entities to certify the competence of… Read More »Should more flexible health care professional licensing continue after COVID-19?

BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis

  • by

Shots: Forbius will receive up front and milestones while BMS will acquire Forbius’s TGF-beta program, including the lead investigational asset, AVID200. The transaction is expected to be closed in Q4’20 Prior to closing, Forbius’ non-TGF-beta assets will be transferred to a newly formed private company,… Read More »BMS to Acquire Forbius for its AVID200 to Expand its Footprints in Oncology and Fibrosis

Vertex’s Kaftrio + Ivacaftor Receive the EC’s Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

  • by

Shots: The EC has granted MAA to Kaftrio (ivacaftor/tezacaftor/lumacaftor) + ivacaftor (150mg) to treat people with CF aged ≥12yrs. with one F508del mutation and one minimal function mutation (F/MF), or two F508del mutations (F/F) in the CFTR gene The MAA is based on two P-III… Read More »Vertex’s Kaftrio + Ivacaftor Receive the EC’s Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

The US FDA Approves Kyprolis (carfilzomib) + Darzalex (daratumumab) + Dexamethasone in Two Dosing Regimens for R/R Multiple Myeloma

  • by

Shots: The US FDA has approved Janssen’s Darzalex + Amgen’s Kyprolis (carfilzomib) and dexamethasone (DKd)  in two dosing regimen (70 mg/m2 , qw and 56 mg/m2 , q2w) for the treatment of adult patients with r/r MM who have received 1-3L therapies The approval of… Read More »The US FDA Approves Kyprolis (carfilzomib) + Darzalex (daratumumab) + Dexamethasone in Two Dosing Regimens for R/R Multiple Myeloma

Drug Repurposing: An Overview 

  • by

This article was originally published by Mahendra Saini, Nikhita Parihar, Shankar Lal Soni, and Vandana Sharma in the Asian Journal of Pharmaceutical Research and Development. 2020; 8(4): 194-212 under an… The post Drug Repurposing: An Overview  appeared first on DrugPatentWatch – Make Better Decisions.

Regeneron Collaborates with Roche to Improve the Global Supply of REGN-COV2 Against COVID-19

  • by

Shots: The two global companies collaborated to develop, manufacture, and distribute REGN-COV2 across the globe. The agreement is expected to increase the supply of REGN-COV2 to at least 3.5 times the current capacity with the potential for expanding it further Regeneron will lead the distribution… Read More »Regeneron Collaborates with Roche to Improve the Global Supply of REGN-COV2 Against COVID-19

Links

  • by

Kamala Harris on health. COVID data quality. African-American views on US health policy. Impact of treatment advances on lung cancer mortality. Trends in deaths of despair.

Pharma Whatsapp Group

  • by

Pharma Whatsapp Group Whatsapp When Join Pharma Pathway Group You get 250+ vacancies direct Your Phone Group Rules – Welcome to Everyone Pharma Pathway Some Rules To Be Followed In This Group: 1. People will be removed from the group without any intimation, if u… Read More »Pharma Whatsapp Group

That Kodak Deal

  • by

Many people have been wondering what’s going on with the announcement by the Trump administration that Kodak has been contracted to produce pharmaceutical APIs here in the US. Let’s line up some of the public statements about all this first, and then take a closer… Read More »That Kodak Deal

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson’s Disease

  • by

Shots: Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD (formerly OXB-102) to treat mod. to sev. PD based on Oxford’s LentiVector platform Axovant is conducting a P-II SUNRISE-PD trial with AXO-Lenti-PD while the dosing of… Read More »Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant to Manufacture and Supply AXO-Lenti-PD for Parkinson’s Disease

Umedica Laboratories -Walk-In Interviews for Freshers & Experienced On 27th to 29th July’ 2020

  • by

Umedica Laboratories -Walk-In Interviews for Freshers & Experienced On 27th to 29th July’ 2020 Umedica Laboratories -Walk-In Interviews for Freshers & Experienced -Manufacturing / Packing / Injection / QA Departments Time & Venue Details : Walk-In On 27th to 29th July’ 2020 At Umedica Laboratories,… Read More »Umedica Laboratories -Walk-In Interviews for Freshers & Experienced On 27th to 29th July’ 2020

WordPress Resources at SiteGround

  • by

WordPress is an award-winning web software, used by millions of webmasters worldwide for building their website or blog. SiteGround is proud to host this particular WordPress installation and provide users with multiple resources to facilitate the management of their WP websites: Expert WordPress Hosting SiteGround… Read More »WordPress Resources at SiteGround

Actiza Pharmaceutical Pvt Ltd. is a strong presence in Injectable manufacturing

Actiza Pharmaceutical Pvt Ltd. is a rapidly growing Indian pharmaceutical company with a strong presence in Injectable manufacturing. Established in 2011, Actiza Pharmaceutical has emerged as one of the largest focused small volume parenteral manufacturer in India and is engaged in contract manufacturing for all… Read More »Actiza Pharmaceutical Pvt Ltd. is a strong presence in Injectable manufacturing